The frequency of simultaneous mutations of TP53 with EGFR or KRAS is higher than 5% in both Western and Asian lung adenocarcinoma patients while it is significantly lower in lung squamous cell carcinoma patients of the two major groups.40 This evidence concerns the gene EGFR and lung adenocarcinoma.